Damora Therapeutics (DMRA) EBITDA (2019 - 2026)

Damora Therapeutics has reported EBITDA for 8 years, with the latest figure at -$27.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 1094.46% year-over-year to -$27.8 million; the trailing twelve-month figure through Mar 2026 stood at -$234.6 million (down 1166.86% YoY), and the FY2025 full-year result was -$209.1 million, down 862.78% from the prior year.
• EBITDA for Q1 2026 stood at -$27.8 million, up from -$200.8 million in the prior quarter.
• The five-year high for EBITDA was -$2.3 million in Q1 2025, with the low at -$200.8 million in Q4 2025.
• Historically, EBITDA has averaged -$21.1 million across 5 years, with a median of -$8.0 million in 2023.
• The largest YoY upside for EBITDA was 57.87% in 2025 against a maximum downside of 2646.71% in 2025.
• Damora Therapeutics' EBITDA stood at -$12.4 million in 2022, then soared by 50.43% to -$6.1 million in 2023, then dropped by 19.02% to -$7.3 million in 2024, then tumbled by 2646.71% to -$200.8 million in 2025, then surged by 86.14% to -$27.8 million in 2026.
• The last three EBITDA figures came in at -$27.8 million (Q1 2026), -$200.8 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.